IMT was originally described in the lungs in 1937, and since then has been reported at various sites such as mesentery, stomach, small intestine, large intestine, liver, mediastinum, retroperitoneum and bladder [
1,
2,
6]. The most common site of IMTs is the lung and the most common sites of extrapulmonary inflammatory myofibroblastic tumor are the mesentery and omentum [
1,
2,
6,
7]. Among extrapulmonary IMT, 43% arose in the mesentery and omentum [
7]. Although it occurs primarily in children and young adults (mean age, approximately 10 years), in more recent years a broad age range has been documented [
1]. There is no difference in incidence between females and males, though each report has a difference in mean age and gender ratio [
2,
5].
The etiology of IMT is still unknown. But some people think that development of IMT occurs after trauma, surgery or infection such as Epstein-Barr virus and human herpes virus related with reactive cytokine production [
6,
7]. A recent study reports that these lesions may possess chromosomal aberrations with resultant monoclonality and may frequently demonstrate locally aggressive behavior. As such, this entity should better be considered a neoplastic process. A chromosomal rearrangement involving 2p23, the site of the
ALK gene, is present in a subset of these tumors [
5]. These findings have recently shown that chromosomal abnormalities may be suggestive of clonal origin, not merely a reactive process. IMT should be considered as a true neoplasm [
5].
Several cases with IMT in the colon have been confirmed in other countries. A total of 5 cases have been reported during the last ten-year period. The patients with IMT presented with anemia, intussusception, fecal occult blood positive, abdominal pain, chest pain, fever or weight loss. Except 1 case, all cases reported were in males. From 32-month-old to 79-year-old, a broad age range of IMT has been documented. The most common site of documented IMT in the colon was the right colon (ascending colon, 2 cases; cecum, 2 cases). IMT in the transverse colon (1 case) was also reported [
1,
3,
4]. A retrospective review of the medical records was conducted at two major academic institutions over a 15-year period by Kovach et al. [
5]. Review of the records from two institutions yielded 44 cases of pathologically confirmed IMT. Among these cases, only 3 cases occurred in colon [
5].
Differential diagnosis of IMT includes malignancy and submucosal tumor from endoscopic findings. In this case, on endoscopic examination, we need to distinguish IMT from lymphoma and submucosal tumor composed of intact mucosal margin. Radiologically differential diagnosis of abdominal IMT includes solitary fibrous tumor and fibromatoses (desmoid tumor).
Inflammatory fibroid polyp, fibromatoses (desmoid tumor), gastrointestinal stromal tumors (GIST), leiomyoma, leiomyosarcoma, and schwannoma have similar pathological findings with IMT. Inflammatory fibroid polyp is typically submucosal and consists of a mixture of small granulation tissue-like vessels, spindle cells, and inflammatory cells (particulary eosinophils). Fibromatoses are composed of bland spindled or stellate cells, arranged in parallel with evenly spaced blood vessels and a collagenous background. Fibromatoses often have mitotic activity, but cytologic pleomorphism is generally not seen. GIST stains for CD34 and CD117 (c-kit). Leiomyoma and leiomyosarcoma stain positively for desmin and actin and negatively for CD117 and CD34. Schwannoma stains strongly for S-100 (nuclear and cytoplasmic) and is CD117 negative [
1,
6,
8]. Immunohistochemically, strong diffuse cytoplasmic reactivity for vimentin is typical for virtually all IMT. Reactivity for smooth muscle actin and muscle specific actin varies from a focal to a diffuse pattern in the spindle cell cytoplasm, and desmin is identified in many cases [
7]. Immunohistochemical cytoplasmic positivity for ALK using a variety of monoclonal antibodies is shown in approximately 50% of IMTs. However, ALK positivity is not specific for IMT [
7]. Because IMT is rare and sometimes similar with malignancy, even after various examinations, it is important to distinguish IMT from other colonic tumors. IMT cannot be diagnosed by preoperation biopsy. Also, the tumor occasionally undergoes malignant transformation if not surgically excised, therefore surgical resection is the treatment of choice. We cannot exclude malignancy completely preoperatively, so it is hard to determine surgical resection margin. We have to understand IMT accurately and be careful to prevent over diagnosis and unnecessary operation and treatment.
Chemotherapy, radiation treatment, nonsteroidal anti-inflammatory drug (NSAID), steroid and cyclosporin-A have been used as treatment modalities, but surgical resection is considered as treatment of choice [
5,
6]. It rarely presents recurrence, metastasis or malignant transformation, and is classified as intermediate neoplasm in the World Health Organization histological typing, but it may recur locally or manifest systemic symptoms. It is for this reason that regular follow-up is necessary even though surgical resection was done [
2,
7].
Several studies have reported that ALK positive tumors have a less aggressive clinical course, although no clear relationship exists between ALK expression and prognosis in IMT [
2,
7,
9,
10]. In addition, there have been some studies that reported a correlation between p53 expression and prognosis [
2,
10]. The role of p53 reactivity in predicting the behavior of IMTs is uncertain [
2,
10]. The etiology of IMT is still unknown, neither reactive process nor neoplasm. And it is unclear about natural course of IMT, unless surgical resection is done.
Most IMTs behave in a benign manner after surgical resection, but it presents recurrence, metastasis or malignant transformation in some cases. It is unclear what kind of factor is associated with prognosis. Also, it is unclear what the best way of treatment of recurrence or metastasis is during long-term follow-up. We have to follow-up patients diagnosed IMT even if they have undergone surgical resection.